drugset
drugset / Trial / NCT00769288

FAU in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00769288 ↗

Phase 1 Completed 12 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy, such as FAU, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. This phase I trial is studying the side effects and best dose of FAU in treating patients with advanced solid tumors or lymphoma.

Timeline

Start
2009-07
Primary completion
2013-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject 2'-F-ara-deoxyuridine Unknown — Intravenous

Indications

Burkitt lymphoma Hodgkins lymphoma MALT lymphoma Waldenstrom macroglobulinemia adult T-cell leukemia/lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma cancer of unknown primary site chronic lymphocytic leukemia/small lymphocytic lymphoma extranodal nasal NK/T cell lymphoma grade III lymphomatoid granulomatosis large-cell immunoblastic lymphoma mantle cell lymphoma mycosis fungoides and variants nodal marginal zone B-cell lymphoma primary cutaneous B-cell lymphoma small intestine lymphoma splenic marginal zone lymphoma